Table 1.
Patient characteristics across three clinical cohorts
| AML02 (N = 167) | AML08 (N = 233) | AAML1031 (N = 854) | P value | |
|---|---|---|---|---|
| Feature | ||||
| Age at diagnosis, y | 10.2 (0.01-21.4) | 9.5 (0.01-19.9) | 8.8 (0.0-29.5) | .778 |
| Sex | .661 | |||
| Male | 94/167 (56.3%) | 123/233 (52.8%) | 448/854 (52.5%) | |
| Female | 73/167 (43.7%) | 110/233 (47.2%) | 406/854 (47.5%) | |
| Race | .031 | |||
| White | 116/167 (69.5%) | 166/233 (70.8%) | 608/854 (71.2%) | |
| Black | 29/167 (17.4%) | 41/233 (17.6%) | 102/854 (11.9%) | |
| Other | 22/167 (11.9%) | 26/233 (11.2%) | 144/854 (16.9%) | |
| Treatment arm | .427 | |||
| Arm A | 88/167 (52.7%) | 108/233 (52.4%) | 409/854 (47.9%) | |
| Arm B | 79/167 (47.3%) | 125/233 (47.6%) | 445/854 (52.1%) | |
| WBC (G/L) | 20 (0-514) | 26 (1-890) | 20 (1-713) | .824 |
| Cytogenetic risk group | <.00001 | |||
| Low | 57/167 (34.1%) | 57/233 (24.0%) | 316/854 (37%) | |
| Standard | 68/167 (40.7%) | 134/233 (57.9%) | 500/854 (58.5%) | |
| High | 42/167 (25.2%) | 42/233 (18.0%) | 25/854 (3%) | |
| Unknown | NA | NA | 13/854 (1.5%) |
Median (range); n/N (%). Arm A, AML02 received low dose cytarabine: LDAC/ AML08 received clofarabine + Ara-C/COG; AAML1031 received standard ADE; Arm B, AML02 and AML08 received high-dose cytarabine (HDAC)/COG; AAML1031 received standard ADE + bortezomib. For AAML1031 cohort only patients from treatment arms A and B were included in this study, which might contribute to lower number in high-risk group category due to exclusion of FLT3-ITD AML.
A, Ara-C or cytarabine; D, daunorubicin; E, etoposide.